Vor Biopharma Inc. (VOR) stock
VORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$19.42+0.10 (+0.52%)
Close on Nov 13, 2026Market cap $1.19BP/E –Yield –
Vor Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
Vor Biopharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $97.24M, down 70.3% year over year. For fiscal 2025 it was $321.53M, up 244.6% from the year before. The highest annual figure on record is $321.53M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $321.53M | +244.6% |
| FY2024 | Dec 31, 2024 | $93.31M | -1.1% |
| FY2023 | Dec 31, 2023 | $94.32M | +46.1% |
| FY2022 | Dec 31, 2022 | $64.55M | +35.8% |
| FY2021 | Dec 31, 2021 | $47.53M | +50.3% |
| FY2020 | Dec 31, 2020 | $31.62M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $34.53M | +144.2% |
| Q2 FY2026 | Jun 30, 2026 | $25.92M | -90.1% |
| Q1 FY2026 | Mar 31, 2026 | $17.60M | -34.1% |
| Q4 FY2025 | Dec 31, 2025 | $19.19M | -24.3% |
| Q3 FY2025 | Sep 30, 2025 | $14.14M | -35.2% |
| Q2 FY2025 | Jun 30, 2025 | $261.50M | +1098.3% |
| Q1 FY2025 | Mar 31, 2025 | $26.70M | +9.8% |
| Q4 FY2024 | Dec 31, 2024 | $25.35M | +21.3% |
| Q3 FY2024 | Sep 30, 2024 | $21.82M | -21.0% |
| Q2 FY2024 | Jun 30, 2024 | $21.82M | -8.7% |
| Q1 FY2024 | Mar 31, 2024 | $24.32M | +11.0% |
| Q4 FY2023 | Dec 31, 2023 | $20.90M | +22.5% |
| Q3 FY2023 | Sep 30, 2023 | $27.61M | +63.6% |
| Q2 FY2023 | Jun 30, 2023 | $23.90M | +55.9% |
| Q1 FY2023 | Mar 31, 2023 | $21.92M | +43.4% |
| Q4 FY2022 | Dec 31, 2022 | $17.06M | +34.4% |
| Q3 FY2022 | Sep 30, 2022 | $16.88M | +30.6% |
| Q2 FY2022 | Jun 30, 2022 | $15.33M | +18.2% |
| Q1 FY2022 | Mar 31, 2022 | $15.28M | +70.9% |
| Q4 FY2021 | Dec 31, 2021 | $12.69M | +12.0% |
| Q3 FY2021 | Sep 30, 2021 | $12.93M | +58.7% |
| Q2 FY2021 | Jun 30, 2021 | $12.97M | +117.1% |
| Q1 FY2021 | Mar 31, 2021 | $8.94M | +44.9% |
| Q4 FY2020 | Dec 31, 2020 | $11.33M | – |
| Q3 FY2020 | Sep 30, 2020 | $8.14M | – |
| Q2 FY2020 | Jun 30, 2020 | $5.98M | – |
| Q1 FY2020 | Mar 31, 2020 | $6.17M | – |
See a number that looks wrong?